Mostrando 4 resultados de: 4
Filtros aplicados
Subtipo de publicación
Article(4)
Immunological evaluation of rheumatoid arthritis patients treated with itolizumab
ArticleAbstract: Rheumatoid arthritis is an autoimmune disease characterized by joint inflammation that affects approPalabras claves:Anti-idiotypic antibody response, Itolizumab, Peripheral lymphocytic counts, Proinflammatory cytokines, Rheumatoid ArthritisAutores:Aira L.E., Carmen Elena Viada, Chico A., Fuentes K.P., Gómez J.A., Gonzalez Z., Hernández P., Mazorra Z., Prada D.M.Fuentes:scopusType 1 diabetes associated and tissue transglutaminase autoantibodies in patients without type 1 diabetes and coeliac disease with confirmed viral infections
ArticleAbstract: Coeliac disease and type 1 diabetes are autoimmune diseases that may share the same initiating envirPalabras claves:Cytomegalovirus, Enterovirus, Epstein-Barr virus, Glutamic acid decarboxylase autoantibodies, Tyrosine phosphatase autoantibodiesAutores:Aira L.E., Cabrera-Rode E., Cilio C.M., Consuelo Beatriz Correa, Cubas-Dueñas I., Fonseca M., Galvan J.A., Hung L.H., Resik S., Sariego S., Sarmiento L.Fuentes:scopusSafety and immunogenicity of a human epidermal growth factor receptor 1 (HER1)-based vaccine in prostate castration-resistant carcinoma patients: A dose-escalation phase I study trial
ArticleAbstract: Metastatic castration-resistant prostate cancer (CRPC) remains incurable due to the lack of effectivPalabras claves:Human epidermal growth factor receptor, Immunogenicity, Prostate cancer, safety, Therapeutic vaccineAutores:Aira L.E., Bárbara Wilkinson, Caballero I., Casacó Parada A.R., Coba K., González J.G., González N., Lavastida A., Luaces P.L.o., Macías A.E., Mazorra Z., Mesa M., Popa X., Rivero J., Sanchez B., Santiesteban Y., Suárez E., Tania Crombet, Troche M.Fuentes:scopusThe anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial
ArticleAbstract: Itolizumab is a humanized anti-CD6 monoclonal antibody (mAb) that has previously shown encouraging rPalabras claves:CD6, Clinical trial, Itolizumab, Phase I, Rheumatoid ArthritisAutores:Aira L.E., Ávila Y., Barrese Y., Carmen Elena Viada, Gómez J.A., Hernández I.M., Hernández M.V., Hernández P., López A.M., Martínez J.P., Milera J.M., Molinero C., Montero E., Moreno E., Prada D.M., Reyes Y., Rodríguez P.C., Torres R.Fuentes:scopus